DNAPrint Announces Another Blood Supply Relationship
SARASOTA, Fla.--(BUSINESS WIRE)--April 12, 2001--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today that the company has entered into a working relationship with Acculab of South Florida to collect and phenotype volunteer blood specimens.
The relationship, which allows DNAPrint to place informed consent "kiosks" at 4 area Acculabs, provides the company with access to a cross-section of South Florida's variable drug responders. By soliciting volunteers at a location where a patient is in the process of having blood drawn for other reasons, DNAPrint hopes to enjoy an unusually high recruitment success rate.
In contrast to web based methods of recruitment, which enjoy high commitment rates but low execution rates, appealing to the volunteer donor at the point of phlebotomy is more likely to immediately and definitively result in banked blood specimens and data.
In contrast to physician based recruitment, which often times focus on particular ethnic and biomedical segments of the population, the company hopes that the relationship announced today will result in an unusually rich collection of phenotype qualified blood specimens which address the nations leading prescription medications.
DNAPrint genomics, Inc. is located in South Florida, in part, to facilitate access to the regions elderly patient population. The average Florida senior is taking numerous medications, and each one has a unique and potentially valuable drug interaction history that can be used for the study of the genetic determinants of variable drug response. This relationship is the companies first with a biomedical "node", where various types of patients from a region cross tracks. To the companies knowledge, it represents a first-of-its-kind relationship within the pharmacogenomics community. The company has previously established blood supply relationships with two other Florida medical facilities that supply the company with biographical and extensive clinical phenotyping data as well.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. --30--mk/mi* CONTACT: DNAPrint genomics Inc., Sarasota For scientific inquiries: Dr. Tony Frudakis, 941/351-4543 or All other inquiries: Richard Craig Hall, 941/341-0136 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com (c) 2000 Business Wire |
